Differential effects of immunosuppressants on lymphocyte function.
In vitro and in vivo parameters of T lymphocyte function were evaluated in guinea pigs following treatment with the "cycle-active" drugs, 6-mercaptopurine (6MP) and methotrexate, and the "non-cycle-active" alkylating agent, cyclophosphamide. Commencing at the time of sensitization to tuberculin protein, animals were treated with an 8 day course of one of the cytotoxic drugs. This regimen either reduced or abolished the cutaneous response to PPD. The two cycle-active drugs inhibited the in vitro lymphoproliferative response to PPD and suppressed the elaboration of migration inhibition factor (MIF) by lymph node cells. However, these agents did not reduce blood lymphocytes, deplete the cellularity of the thymic dependent areas of peripheral tissues, or alter the in vitro response of lymph node cells to the nonspecific mitogen PHA. In contrast, treatment with cyclophosphamide was associated with a reduction in peripheral blood and tissue lymphocytes and impaired responses to PHA by residual lymph node cells. In vitro proliferative responses to PPD were inhibited but the capacity of lymph node cells to elaborate MIF was not suppressed. In addition to their effects on antigen-reactive lymphocytes, all three drugs significantly reduced the number of macrophages in induced peritoneal exudates. With respect to immunosuppressive activities, results of these investigations suggest that the noncycle-active agents affect both intermitotic and dividing T lymphocytes without impairing certain intermitotic functions of residual cells. The cycle-active drugs have a more restricted toxicity limited to those T lymphocytes which have been stimulated to undergo active DNA synthesis by antigenic challenge.
D000818:Animals; D002464:Cell Migration Inhibition; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D005620:Freund's Adjuvant / Q000008:administration & dosage; D006168:Guinea Pigs; D007111:Immunity, Cellular; D007114:Immunization; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000494:pharmacology; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D014373:Tuberculin / Q000008:administration & dosage; D014374:Tuberculin Test
D007166:Immunosuppressive Agents; D037102:Lectins; D014373:Tuberculin; D003520:Cyclophosphamide; D005620:Freund's Adjuvant; D015122:Mercaptopurine; D008727:Methotrexate